You are here: Home: Audio Program Guide: American Society of Breast Surgeons Annual Meeting 2008 - Audio: American Society of Breast Surgeons Annual Meeting 2008
 
  Go to Panel Discussion
Go to interview with J Michael Dixon, MD
Go to interview with Peter M Ravdin, MD, PhD
Go to interview with Mark D Pegram, MD
Go to interview with Pat W Whitworth Jr, MD
  To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
  Panel Discussion

  
  Click here to download the entire discussion  
Track 1 Timing of sentinel lymph node biopsy (SLNB) relative to neoadjuvant systemic therapy
Track 2 Use of neoadjuvant chemotherapy versus endocrine therapy
Track 3 Use of the Oncotype DX® assay to identify patients with hormone receptor-positive, node-negative breast cancer who may benefit from chemotherapy
Track 4 Data with the Oncotype DX assay in node-positive breast cancer
Track 5 Development and validation of the Oncotype DX versus MammaPrint® assay
Track 6 Reliability of hormone receptor testing

Track 7 Long-term risk of recurrence in hormone receptor-positive early breast cancer
Track 8 Preliminary results of the ATLAS trial: Five versus 10 years of adjuvant tamoxifen
audio
Track 9 ATAC trial 100-month update: “Carryover effect” with adjuvant aromatase inhibitors (AIs)
audio
Track 10 Clinical perspectives on the efficacy of letrozole versus anastrozole
audio
Track 11 Extended adjuvant endocrine therapy with AIs
audio
Track 12 AIs and bone health
audio
Track 13 Quality of life with AIs compared to tamoxifen
Track 14 Site of injection during SLNB
Track 15 Management of cases with a microscopically positive sentinel lymph node
audio
Track 16 Quality control in HER2 testing
audio
Track 17 Anthracycline- versus nonanthracycline-containing chemotherapy in combination with adjuvant trastuzumab
audio
Track 18 Adjuvant TCH (docetaxel/carboplatin/trastuzumab) in the treatment of HER2-positive early breast cancer
audio
Track 19 Use of and contraindications for partial breast irradiation (PBI)
Track 20 Use of MRI in breast cancer
     
Dixon, MD J Michael Dixon, MD
Consultant Surgeon and
Senior Lecturer
Academic Office
Edinburgh Breast Unit
Western General Hospital
Edinburgh, United Kingdom		  
  Click here to download the entire interview  
Track 1 Neoadjuvant endocrine therapy versus chemotherapy for patients with hormone receptor-positive tumors
Track 2 Duration of neoadjuvant endocrine therapy and rate of breast-conserving surgery
Track 3 Differential potency of AIs: Impact on efficacy and bone health
Track 4 Timing of SLNB for patients treated with neoadjuvant therapy
Track 5 Use of ultrasound of the axilla during preoperative assessment
Track 6 Approach to the axilla in patients with a negative SLNB but positive nodes identified on permanent section

Track 7 Number of sentinel lymph nodes identified during SLNB
Track 8 Utilization, timing and injection site of technetium and/or blue dye
Track 9 Patterns of care in surgeons with respect to prescribing adjuvant endocrine therapy
Track 10 Adjuvant endocrine therapy and bone health
Track 11 Overall survival as an endpoint in clinical trials of adjuvant endocrine therapy
Track 12 Management of AI-associated arthralgias
Track 13 Carryover effect with anastrozole in the ATAC trial 100-month update
Track 14 Continuing adjuvant AIs after completion of five years of therapy
Track 15 Natural history of hormone receptor-positive breast cancer and prolonged risk of relapse
Track 16 Novel adjuvant treatment strategies in hormone receptor-positive breast cancer
Track 17 Preliminary analysis of the ATLAS trial: Implications of benefit from longer-term tamoxifen for premenopausal patients
Track 18 Identification of patients likely or unlikely to benefit from adjuvant chemotherapy
Track 19 Comparison of the Oncotype DX and MammaPrint assays
Track 20 Postmastectomy radiation therapy for patients with one to three positive nodes
     
Peter M Ravdin, MD, PhD
Research Professor of Biostatistics
The University of Texas
MD Anderson Cancer Center
Houston, Texas		  
  Click here to download the entire interview  
Track 1 Perceptions of surgeons of the use of adjuvant chemotherapy by medical oncologists
Track 2 Identification of patients with lower-risk, hormone receptor-positive breast cancer likely or unlikely to benefit from adjuvant chemotherapy
Track 3 Tissue requirements for the Oncotype DX and MammaPrint assays
Track 4 TAILORx: Hormone therapy with or without chemotherapy for patients with node-negative early breast cancer and midrange Recurrence Scores®
Track 5 Endorsement of the Oncotype DX assay by major cancer guideline committees
Track 6 Critical appraisal of the MammaPrint assay
audio
Track 7 Clinical utility of the Oncotype DX assay for node-positive breast cancer
audio
Track 8 Long-term risk of recurrence in hormone receptor-positive breast cancer: Rationale for extended adjuvant endocrine therapy
audio
Track 9 Implications of the ATLAS trial for prolonged adjuvant tamoxifen in premenopausal patients
audio
Track 10 Lack of toxicity data in the ATLAS trial
Track 11 Switching patients from adjuvant tamoxifen to an AI after the onset of menopause
Track 12 Clinical trials evaluating adjuvant AIs for longer than five years
Track 13 Monitoring bone health in patients treated with adjuvant AIs
Track 14 Perspective on the lack of survival advantage with adjuvant AIs compared to tamoxifen
audio
     
Pegram, MD Mark D Pegram, MD
Director for Translational
Research Program
Braman Family Breast Cancer
Research Institute
UM Sylvester Comprehensive
Cancer Center
Miami, Florida		  
  Click here to download the entire discussion  
Track 1 Quality controls to ensure consistency with modern diagnostic assays
Track 2 Clinical implications of false-negative ER or HER2 results
Track 3 Incidence of HER2-positive breast cancer
Track 4 ASCO/College of American Pathologists (CAP) guidelines for HER2 testing
Track 5 Complexities in the performance and interpretation of FISH for HER2
audio
Track 6 Retesting with FISH for tumors identified as IHC 1+ for HER2
audio
Track 7 Algorithm for FISH testing in the ASCO/CAP guidelines
audio
Track 8 Quantitative ER and HER2 assessment with the Oncotype DX assay
audio
Track 9 Clinical approach to patients with FISH ratios in the equivocal range (1.8-2.2)
Track 10 HER2 status and benefit from adjuvant trastuzumab
Track 11 Potential benefit of adjuvant trastuzumab for “HER2-negative” tumors
Track 12 Potential immunologic mechanism of action of trastuzumab in the adjuvant setting
Track 13 Lack of correlation between HER2 copy number and benefit from trastuzumab
audio
Track 14 Effect of trastuzumab and chemotherapy on cardiac function
audio
Track 15 Nonanthracycline-containing chemotherapy in combination with trastuzumab
audio
Track 16 Surgeons’ perceptions of trastuzumab-associated side effects
audio
Track 17 Considerations in the early incorporation of therapies into the adjuvant setting
audio
     
Whitworth, MD Pat W Whitworth Jr, MD
Director, Nashville Breast Center
Clinical Associate Professor of Surgery
Vanderbilt University
Nashville, Tennessee		  
  Click here to download the entire interview  
Track 1 Timing of SLNB for patients receiving neoadjuvant systemic therapy
Track 2 Potential impact of performing SLNB before neoadjuvant therapy on treatment decision-making
Track 3 Relationship between number of sentinel nodes removed and false-negative rate
Track 4 Preoperative assessment of the axilla with ultrasound and fine needle aspiration
Track 5 Contraindications for PBI
audio
Track 6 Use of MRI in breast cancer
audio
Track 7 Identification of patients likely to benefit from adjuvant chemotherapy
audio
Track 8 Development and clinical utility of the Oncotype DX and MammaPrint assays
audio
Track 9 MammaPrint versus Oncotype tissue requirements
Track 10 Prognostic and predictive utility of Oncotype DX for patients with hormone receptor-positive, node-positive tumors